{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 141,
  "pageCount": 415,
  "prevPage": 140,
  "nextPage": 142,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The red box highlights the 30.4% peripheral edema rate. The text argues that the conflation of data between the P3 study and the extension study is an intentional attempt to hide worsening safety profiles.",
  "elementsJson": [
    "paragraph",
    "data_table",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/141",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-141",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The prevalence of edema appears to increase the longer that Vykat is used, with no apparent plateau – indicating that a tipping point is eventually reached whether discontinuation or a safety event.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a1-a298fc2e856d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Peripheral edema: 30.4%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a1-a6f6c0a49f82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The prevalence of edema appears to increase the longer that Vykat is used, with no apparent plateau – indicating that a tipping point is eventually reached whether discontinuation or a safety event. The open-label P3 extension study (C602) indicates edema in 30.4% of patients – exceeding the 20% in the Phase 3 paper. The average patient age in C602 was only 13.4 years. However, there is no way to extract the adverse events from the 1-year extension study because they are conflated with the previously reported P3 double-blind placebo-controlled study – which suggests an attempt to conceal longer-term rates of edema during the extension period.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a24af256-f053-44b2-9c3e-2312aaf497a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.43,
        "x": 0.07,
        "y": 0.945
      },
      "kind": "source-note",
      "text": "Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC12181816/pdf/nihms-2090141.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ff99be5-1cdd-410d-9b68-341fd1c304aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.08,
        "y": 0.45
      },
      "kind": "table",
      "text": "Clinical Studies C601+C602 Summary of Drug-Related Treatment Emergent Adverse Events",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33da16d4-1b13-42e1-9564-c8015ba904d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.68,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "title",
      "text": "Phase 3 open-label extension study (C602) – adverse events table",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38149a46-619f-4cbc-9884-840d2f64674d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "639a4a53-ad58-44f8-8699-50a950f8de13",
      "evidence": "The slide explicitly claims an 'attempt to conceal' safety data through data conflation.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}